Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Why Avantor Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Unique Fabricating, Inc. (NYSE: UFAB) shares jumped 113% to $0.4605 after gaining 12% on Thursday. 
Via Benzinga
News headline image
Biogen (NASDAQ: BIIB) Acquires Reata (NASDAQ: RETA) to Boost its Neurological Therapeutics Portfolio, Including SKYCLARYS®
Reata's Acquisition to Propel Biogen's Growth Strategy Biogen Inc. (NASDAQ: BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have announced a 
Via Spotlight Growth
News headline image
Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals ↗
 
Via Benzinga
News headline image
Expert Ratings for Reata Pharmaceuticals ↗
 
Via Benzinga
Reata Pharmaceuticals Inc. (NASDAQ: RETA) is a Stock Spotlight on 7/17
Via Investor Brand Network
News headline image
Dow Surges 250 Points; Exxon Mobil Earnings Miss Expectations ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 250 points on Friday. The Dow traded up 0.72% to 35,535.23 while the NASDAQ rose 1.89% to 14,316.53. The S&P 500,... 
Via Benzinga
News headline image
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated ↗
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
News headline image
Skechers, Chart Industries, Roku, Beazer Homes And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) rose... 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Reata Pharmaceuticals ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Reata Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Is QuantumScape (QS) Stock Up 10% Today? ↗
QuantumScape (QS) stock is continuing to rally on Friday following an update from its latest earnings report and EV battery plans. 
Via InvestorPlace
News headline image
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today? ↗
Reata Pharmaceuticals (RETA) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (BIIB). 
Via InvestorPlace
News headline image
Nasdaq Jumps 200 Points; Procter & Gamble Posts Upbeat Earnings ↗
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.39% to 35,419.43 while the NASDAQ rose... 
Via Benzinga
News headline image
Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals ↗
Reata stock surged more than 50% on the news. 
Via Investor's Business Daily
News headline image
Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B ↗
Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Biogen to Acquire Reata Pharmaceuticals
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
Each has the potential to dramatically outperform the market. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023 ↗
 
Via Benzinga
News headline image
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review ↗
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
News headline image
Reata Surges 16% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug ↗
The company can now launch its Friedreich's ataxia treatment, Skyclarys. 
Via Investor's Business Daily
News headline image
Reata Nears Breakout After Snagging FDA Blessing To Launch Its Friedreich's Ataxia Drug ↗
The company has now launched its treatment for Friedreich's ataxia, despite numerous obstacles. 
Via Investor's Business Daily
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on! 
Via InvestorPlace
News headline image
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Reata, DLocal, Comerica, and Advance Auto Parts and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Top 1% Biotech Stock Reata Pharmaceuticals Faces Another Hurdle ↗
Reata Pharmaceuticals took another step toward launching its highly anticipated drug, Skyclarys. 
Via Investor's Business Daily
News headline image
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
From Reata Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. 
Via Benzinga
News headline image
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
From Reata Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.